CAJ | 학술논문

无载体放射性碘标记间碘苄胍(no-carrier-added,n.c.a.123/131 I-MIBG)在肿瘤、心肌显像和神经内分泌肿瘤的治疗方面有理论上优势。首先合成了以多氟化合物为支持体的标记前体,对该前体进行了放射性碘标记、纯化和初步生物分布实验。结果显示,无载体放射性碘125 I 标记 MIBG 在正常小鼠的心、脾、肺和肾上腺中的摄取显著高于目前商用的放射性碘标记 MIBG。利用该方法标记后产物不需要使用 HPLC 进行纯化,适用于大规模临床应用。
무재체방사성전표기간전변고(no-carrier-added,n.c.a.123/131 I-MIBG)재종류、심기현상화신경내분비종류적치료방면유이론상우세。수선합성료이다불화합물위지지체적표기전체,대해전체진행료방사성전표기、순화화초보생물분포실험。결과현시,무재체방사성전125 I 표기 MIBG 재정상소서적심、비、폐화신상선중적섭취현저고우목전상용적방사성전표기 MIBG。이용해방법표기후산물불수요사용 HPLC 진행순화,괄용우대규모림상응용。
No-carrier-added meta-[?I]iodobenzylguanidine((n.c.a.)[1 23/1 3 1 I]MIBG)has been considered to be promising diagnostic agents for oncology and cardiology,or as tar-geted radiotherapeutics for neuroendocrine tumors.The synthesis of a fluorous suppor-ted precursor for the purification without HPLC of n.c.a.[?I]MIBG was presented and its structure was determined.The precursor was labeled with radioactive iodine and the preliminary biodistribution of n.c.a.[?I]MIBG was studied.The uptake of n.c.a.[1 2 5 I] MIBG were significantly higher than that of c.a.[1 2 5 I]MIBG in heart,spleen,lung and adrenals.This facile preparation method of n.c.a.[?I]MIBG would allow its wider application in clinic.